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Summary
Colorectal cancer is the 3rd most common malignant disease worldwide and it represents 
the major public health issue. Nowadays, multidisciplinary approach is common in diagnostics 
and treatment of all malignant diseases, rectal cancer is an example for importance of vario-
us medical disciplines collaboration in achieving optimal treatment outcome. This paper is a 
short overview of most important clinical trials which defined optimal therapeutical approach 
to the patients with locally advanced rectal cancer. Actual guidelines and recommendations 
for treatment of patients with stage II or III rectal cancer include preoperative radiotherapy (RT) 
with or without concurrent chemotherapy, and radical surgical resection (with mandatory total 
mesorectal excision-TME). Such multidisciplinary approach to the therapy of these patients si-
gnificantly reduced rates of local recurrence, and increased likelihood of pathologic complete 
response and sphincter-preserving surgery, with low rates of acute treatment toxicity. In order to 
further improve treatment outcomes, there are ongoing studies which investigate novel systemic 
drugs (immunotherapy-antibody-drug conjugates) as well as modern radiotherapy techniques 
(IMRT- intensity modulated RT, IGRT- image guided RT, VMAT- volumetric modulated arch RT) 
in patients with rectal cancer . 
Keywords: rectal cancer; preoperative (neoadjuvant) chemoradiotherapy; total mesorectal 
excision; multidisciplinary treatment.
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Colorectal cancer is the third most commonly diagnosed cancer in males and 
the second in females, with 1.4 million new cases and 690.000 deaths estimated to 
have occurred in 2012 worldwide [1]. Rates are substantially higher in males than in 
females. Nowadays, it is generally considered that significant percentage of rectal 
cancer is connected to lifestyle risk factors, such as obesity (especially abdominal), 
increased consumption of red and processed meat, physical inactivity, smoking and 
heavy alcohol use, and only about 10% is caused by inherited genetic syndromes 
(FAP, HNPCC, Turcots syndrome, Peutz-Jeghers syndrome). Some calculations pre-
dict that 2.4 million cases of colorectal cancer will be diagnosed annually worldwide 
by 2035. More than 95% of colorectal cancers are adenocarcinomas originating from 
epithelial cells of the colorectal mucosa, other rare versions are adenosquamous 
carcinoma, mucinous adenocarcinoma, signet-ring cell carcinoma, medullary, ne-
uroendocrine and undifferentiated carcinoma [2]. The proportion of rectal cancer 
among cancers of the large intestine (colorectum) varies from 27% to 58%, depen-
ding on the cancer registry and classification of recto-sygmoid tumors. 
Rectal cancer is a typical example for importance of multidisciplinary approach 
in the treatment of malignant disease. Disciplines involved in the care for rectal can-
cer patients (from diagnosis and treatment to posttreatment rehabilitation) include: 
radiology, pathology, molecular biology, abdominal surgery, anesthesiology, medi-
cal oncology, radiation oncology and rehabilitational medicine. This text focuses on 
multidisciplinarity in the treatment of rectal cancer patients. 
From the beginnings of rectal cancer treatment, it was evident that surgery alo-
ne is not sufficient treatment, since there was high proportion of patients with local 
or distant failure after tumor resection (with exception of patients with early, stage 
I tumors). Adjuvant radiotherapy with or without chemotherapy has been widely 
used for decades in order to improve outcomes in patients with rectal cancer. For 
locally advanced disease, postoperative chemoradiotherapy significantly improves 
both local control and overall survival as compared with surgery alone or surgery 
plus irradiation [3]. This information prompted a National Institutes of Health (NIH) 
consensus conference, convened in 1990, to recommend postoperative adjuvant che-
moradiotherapy as standard treatment for patients with rectal cancer classified as 
stage II (i.e., a tumor penetrating the rectal wall, without regional lymph-node in-
volvement) or stage III (i.e., any tumor with regional lymph-node involvement) [4].
In the last two decades numerous multidisciplinary clinical trials that addre-
ssed effects of preoperative (neoadjuvant) or postoperative (adjuvant) radiotherapy 
with or without chemotherapy for patients with rectal cancer have been conducted. 
Advantages of preoperative irradiation (as opposed to postoperative RT) are related 
to both tumor response and normal tissue preservation. First, reduction of tumor 
199
Rad 522. Medical Sciences, 41(2015) : 197-207
Z. Rendić-Miočević, A. Juretić, L. Beketić-Orešković: The importance of multidisciplinary approach in the treatment of rectal cancer
volume prior to surgery may facilitate complete resection and increase the likeliho-
od of sphincter-sparing procedure. Also, irradiation of intact tissue (surgery-naive 
ie. better oxygenated) may result in increased sensitivity to RT. With preoperative 
radiotherapy, radiation-induced injury to small bowel trapped in the pelvis by po-
stoperative adhesions, can be avoided. Preoperative RT targets tissues and structu-
res that will be resected afterwards, which increases the likelihood of performing 
an anastomosis with healthy colon. Before the decision of neoadjuvant treatment, 
staging with pelvic magnetic resonance imaging (MRI) is obligatory. One potential 
disadvantage of using neoadjuvant approach is the possibility of over-treating ear-
ly stage (stage I) rectal tumors which, based on definitive patohistological finding, 
don’t require adjuvant therapy. 
There are currently two main approaches of preoperative pelvic radiotherapy 
for resectable rectal cancer: short-course irradiation and long-course chemoradiot-
herapy. Although the radiation techniques and target volumes are similar, the frac-
tionation and timing of surgery differ. In general, short-course radiation delivers 
25 Gy (5 Gy/fraction in 5 fractions) of radiation followed by surgery 1 week later. 
Long-course chemoradiotherapy delivers 50.4 Gy (1.8 Gy/fraction in 28 fractions) of 
radiation concurrently with chemotherapy (usually fluoropyrimidines or its deriva-
tives) followed by surgery 4 to 8 weeks later. These competing approaches evolved 
in parallel; short-course radiation developed in northern Europe and Scandinavia 
and long-course chemoradiotherapy (CRT) in the United States and selected Euro-
pean countries. 
Two landmark trials support the use of short-course preoperative radiation. In 
1997. Swedish Rectal Cancer Trial group published results of multicentric clinical 
trial investigating effects of preoperative neoadjuvant radiotherapy on local control 
and overall survival in rectal cancer patients [5]. 1168 patients were randomized into 
two arms: radiotherapy arm, where patients were preoperatively treated with short-
course radiotherapy (25 Gy in 5 fractions; surgery was performed within one week 
after completion of RT) and control arm where patients received only surgical trea-
tment (anterior or abdominoperineal resection). The irradiation did not increase po-
stoperative mortality. After five years of follow-up, the rate of local recurrence was 
11% in the group that received radiotherapy before surgery and 27% in the group 
treated with surgery alone (P<0.001). This difference was present in all subgroups 
of patients defined according to Dukes’ classification. The overall five-year survival 
rate was 58% in the radiotherapy-plus-surgery group and 48% in the surgery-alone 
group (P=0.004). The cancer-specific survival rates at nine years among patients tre-
ated with curative resection were 74% and 65%, respectively (P=0.002). The Swedish 
Rectal Cancer Trial was one of the first clinical trials that showed clear benefit of 
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preoperative radiotherapy not only in terms of local recurrence rate reduction but in 
terms of improved survival as well. This was the only randomized trial which has 
revealed a significant advantage in survival. 
The results prompted Dutch group of authors to conduct the CKVO 95-04 trial [6] 
which used the same design but mandated surgeons to use of total mesorectal excisi-
on (TME): 1861 patients with resectable rectal cancer and without evidence of metasta-
tic disease were randomly assigned (ratio 1:1) to TME preceded by short-course (25 Gy 
in 5 fractions) pelvic irradiation or TME alone. 10-year cumulative incidence of local 
relapse was 5% in the RT+TME group and 11% in the TME-alone group (p<0·0001). The 
effect of radiotherapy became stronger as the distance from the anal verge increased, 
but only in patients with a positive circumferential resection margin. Overall survival 
did not differ between the two arms. For patients with TNM stage III cancer with a 
negative circumferential resection margin, 10-year survival was 50% in the RT+TME 
arm versus 40% in the TME-alone group (p=0·032). Both the initial and long-term re-
ports revealed a significant improvement in local control with preoperative radiation, 
although no difference in overall survival was observed.
The German Rectal Cancer trial [7] long term follow up results, reported in 2012. 
compared preoperative and postoperative CRT. In this trial, 799 eligible patients 
with stage II/III rectal cancer were randomised to preoperative CRT (50,4 Gy in 28 
fractions + FU 1000 mg/m2 during the first and fifth weeks of radiotherapy), TME 
surgery, and adjuvant FU chemotherapy, or the same schedule of CRT used posto-
peratively (postoperative arm received an additional boost dose of 5,4 Gy on the 
tumor bed). 10-year overall survival was 59.6% in the preoperative arm and 59.9% in 
the postoperative arm (P = 0.85). The 10-year incidence of local relapse was 7.1% and 
10.1% in the pre- and postoperative arms, respectively (P = 0.048). No significant dif-
ferences were detected for 10-year cumulative incidence of distant metastases (29.8% 
and 29.6%; P =0 .9) and disease-free survival. Preoperative approach was superior in 
terms of treatment compliance, toxicity, tumor downstaging, sphincter preservation 
and 5-year local control. This trial changed the standard of care for patients with 
cT3-4 and/or N+ disease to preoperative longcourse chemoradiotherapy in Germa-
ny, most parts of Europe, and the USA.
There is still an ongoing controversy about optimal preoperative approach. The 
first randomized trial comparing short-course RT vs. Long- course CRT in patients 
with resectable cT3-4 rectal cancer was published by Bujko et al. [8]. The aim of the 
study was to compare overall survival, local control and late toxicity in 312 patients 
randomized in two treatment groups: short-course RT group (25 Gy in 5 fractions; 
surgery within 7 days) or long-course CRT group (50.4 Gy in 28 fractions of 1.8 Gy, 
bolus 5-FU/LV; surgery 4-6 weeks later). Acute toxicity was higher in the CRT group 
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(18.2% vs. 3.2%; P < 0.001). Although the long-course chemoradiotherapy arm had 
lower incidence of positive radial margins (4% vs. 13%; P = .017), there were no si-
gnificant differences in crude local recurrence rates (9% vs. 14%; P = 0.170) or 4-year 
survival (66.2% vs. 67.2%; P = 0.960). Severe late toxicity was 10.1% vs. 7.1% (P = 0.360), 
respectively.
TROG 01-04 [9] is a multicenter randomized trial in which 326 patients with 
cT3Nx adenocarcinoma located in the lower 2/3 of the rectum were randomly assi-
gned to short-course(SC) RT versus long-course (LR) CRT. Patients in both arms re-
ceived 6 months of postoperative adjuvant chemotherapy. Rates of local recurrence 
after 3-year follow-up were 7.5% for SC vs. 4.4% for LC (P=0.24); 5-year distant recu-
rrence rates were 27% for SC vs. 30% for LC (P=0.92). Overall survival rates at 5 years 
were 74% for SC vs. 70% for LC (P=0.62).Late toxicity rates were not substantially di-
fferent (SC 5.8% vs. LC 8.2%; P=0.53). A subset analysis of the 79 patients with distal 
tumors revealed a cumulative incidence of local recurrence of 12.5% in SC arm vs. 
0% in LC arm. Although LC chemoradiotherapy arm had a 3% lower local recurren-
ce rate at 3 years and a 2% lower local recurrence rate at 5 years, neither were stati-
stically significant. Authors conclude that the results of local recurrence rates have 
either no clinically important difference or speak in favor of LC chemoradiation. 
Also, LC could be more effective in reducing local recurrence rates for distal tumors.
Surgery of rectal cancer also experienced important improvements in the last 
two decades. TME (total mesorectal excision) is a surgical technique which was 
introduced into surgical practice and became widely used in rectal cancer surge-
ry during 1990’s. A significant length of the bowel around the tumor is removed, 
together with the belonging lymphatic drainage. The term total mesorectal excision 
strictly applies when performing a low anterior resection for tumors of the middle 
and the lower rectum, wherein it is essential to remove the rectum along with the 
mesorectum up to the level of the levator muscles. The principles of TME are also 
applied during an abdominoperineal excision of the rectum and for tumors of the 
upper rectum, although these are considered distinct from standard TME. In an 
abdominoperineal excision of the rectum where the tumor exists below the level of 
the levators, the lateral margins of the tumor are inferior to the mesorectum and the 
benefits of total mesorectal excision do not apply. Anterior resections involving the 
upper rectum may be completed with mobilization of the rectum to beyond 5 cm 
of the lower margin of the tumor, and which is often above the level of the levator 
and is sometimes referred to as partial mesorectal excision. TME results in a lower re-
currence rate than traditional approaches and a lower rate of permanent colostomy. 
Postoperative recuperation is somewhat increased over competing methods. When 
practiced with diligent attention to anatomy there is no evidence of increased risk 
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of urinary incontinence or sexual dysfunction [10]. TME is now considered the gold 
standard for tumors of the middle and the lower rectum.
Chemotherapy used to treat rectal cancer can be categorized into one of two 
large groups: chemotherapy that is part of pre- or postoperative treatment (usually 
applied concommitantly or sequentially with pelvic irradiation) and chemotherapy 
for metastatic colorectal cancer. This text will be focused on chemotherapy in neoa-
djuvant and adjuvant setting in combination with radiotherapy. 
A number of randomized clinical trials have evaluated and confirmed the effec-
tiveness of adding chemotherapy to radiation in preoperative setting after clinical/
radiological staging, as well as in postoperative adjuvant treatment, following patho-
logical staging in patients with locally advanced rectal cancer. Benefits of addition of 
chemotherapy concurrent with pelvic irradiation include: local senzitization of tumor 
tissue (and normal tissue as well, but to a lesser extent), systemic control of the disease 
by eradicating possible micrometastases, increased likelihood of pathologic complete 
response and sphincter preservation. Drugs applied concurrently with radiotherapy 
are primarily radiosensitizing agents, with main intent to make irradiated (tumor) 
tissue more responsive to radiation-induced cell injury and/or death. 5-fluorouracil 
(5-FU), given either as an iv. infusion or orally (as prodrug capecitabine, that is enzy-
matically converted to (5-FU) in the body), appears to have the most favorable balance 
of efficacy and tolerability at the present time, so it is routinely used in concommitant 
chemoradiotherapy for rectal cancer. Oral administration without need for central IV 
access makes capecitabine an attractive and increasingly used option. Oxaliplatin and 
irinotecan have also been evaluated in neoadjuvant setting, but both demonstrated 
increased toxicity without substantial associated improvement in outcomes. There is 
currently a great need for finding new radiosensitizing agents and predictive biomar-
kers to help optimize the use of existing therapeutics. 
A group of French authors published results of a clinical trial (FFCD 9203) which 
compared preoperative radiotherapy with and without concurrent chemotherapy 
[11]. 733 patients with T3-4NxM0 rectal adenocarcinoma were randomized into: RT 
group (preoperative radiotherapy with 45 Gy in 25 fractions; surgery planned 3-10 
weeks after RT completion) and CRT group (same treatment protocol with addition 
of 5-FU 350 mg/m2 + leucovorin (lV) 20 mg/m2 during weeks 1 and 5 of RT). All 
patients received adjuvant chemotherapy with the same 5-FU/LV regimen. Althou-
gh patients in the CRT group had significantly higher rates of pathologic complete 
response (11.4% vs 3.6%; P < 0.05) and less local recurrences (8.1% vs. 16.5%; P<0.05) 
there was no benefit of adding chemotherapy to preoperative RT in terms of 5-year 
overall survival (67.9% vs. 67.4%; P=0.684). Also, patients in CRT group had higher 
frequency of grade 3 and 4 acute toxicity (14.6% vs 2.7%;P <0 .05). Preoperative con-
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current chemoradiotherapy despite a moderate increase in acute toxicity and no im-
pact on overall survival significantly improves local control and is recommended 
for T3-4, N0-2, M0 adenocarcinoma of the middle and distal rectum.
EORTC 22921 phase III trial [12,13] evaluated effects of adding chemotherapy 
to preoperative pelvic irradiation and the value of postoperative chemotherapy on 
survival improvement in patients with T3-4 resectable rectal cancer. Preoperative 
trial design was similar to French study, except patients were also randomized into 
two groups depending on whether they received postoperative chemotherapy or 
not. Patients (n=1011) were allocated to the following four arms: arm 1, preoperative 
RT 45 Gy in 25 fractions; arm 2, preoperative CRT (addition of 5-FU 350 mg/m2 + 
lV 20 mg/m2 during weeks 1 and 5 of RT); arm 3, preoperative RT + 4 courses of 
postoperative chemotherapy; and arm 4, preoperative CRT + 4 courses of postopera-
tive chemotherapy. Addition of chemotherapy to preoperative irradiation resulted 
in enhanced tumoricidal effect of radiotherapy: significant reductions in tumor size, 
pTN stage and lymphatic, vascular and perineural invasion were observed in pre-
operative CRT group compared to preoperative RT only. There was no significant 
difference in overall survival between the groups that received chemotherapy preo-
peratively (P=0.84) and those that received it postoperatively (P=0.12). The combined 
5-year overall survival rate for all four groups was 65.2%. The 5-year cumulative in-
cidence rates for local recurrences were 8.7%, 9.6%, and 7.6% in the groups that rece-
ived chemotherapy preoperatively, postoperatively, or both, respectively, and 17.1% 
in the group that did not receive chemotherapy (P=0.002). Finally authors conclude 
that chemotherapy, regardless of whether it is administered before or after surgery, 
confers a significant benefit with respect to local control. Although chemotherapy 
had no significant effect on overall survival between the arms, its use in combinati-
on with preoperative RT is highly encouraged since it induces downsizing, down-
staging, and significant changes in histologic tumor characteristics.
In 2012. Bonnetain et al. published results of pooled analysis of EORTC 22921 
and FFCD 9203 trials [14]. Using meta-analysis methodology, this trial established 
that addition of 5FU-based chemotherapy to preoperative radiotherapy improves 
pathological complete response (pCR) and local control (LC) rates. Compared to 
only preoperative RT, CRT did not prolong overall survival (OS) or progression-free 
survival (PFS). This trial also evaluated strength of certain pathological and clinical 
parameters as potential surrogates for OS (identifying surrogate end points for long-
term clinical outcomes such as OS would allow clinicians to reduce trial duration 
as well as assess their patients’ prognosis during or shortly after the treatment). The 
authors stated that pathologic complete response pCR) and local control (LC) cannot 
qualify as reliable surrogates for PFS or OS. 
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In the ACCORD-12 trial [15,16] two neoadjuvant chemoradiotherapy protocols 
are compared in terms of outcome parameters as well as toxicity. A total of 598 pa-
tients with T3-4N+ resectable rectal cancer were randomly assigned to preoperative 
concurrent chemoradiotherapy with CAP45 (45 Gy in 25 fractions with concurrent 
capecitabine) or CAPOX50 (50 Gy in 25 fractions with concurrent capecitabine + oxa-
liplatin). Surgery was performed 6 weeks after CRT completion. Pathologic complete 
response (sterilization of the operative specimen) was achieved in 13.9% vs.19.2% 
of patients, respectively (P=0 .09). After 3-year follow-up, there was no significant 
difference between local recurrence rates (6.1% vs. 4.4%), overall survival (87.6% vs. 
88.3%) or disease-free survival (67.9% vs. 72.7%). More preoperative grade 3 to 4 
toxicity occurred in the CAPOX50 group (25 v 1%; P < .001). In conclusion authors 
suggest that the benefit of oxaliplatin was not demonstrated and its use with concu-
rrent irradiation is not recommended.
Interestingly designed RAPIDO trial [17] is a two-arm prospective randomi-
zed multicentric trial comparing conventional preoperative long-course concurrent 
chemoradiotherapy (45-50 Gy in 25 fractions with capecitabine) with introductory 
short-course radiotherapy (25 Gy in 5 fractions) followed by 6 cycles of chemothera-
py (capecitabine and oxaliplatin) before surgery. The hypothesis is that short-course 
radiotherapy with neo-adjuvant chemotherapy increases disease-free and overall 
survival without compromising local control. The trial is still ongoing and oncolo-
gists worldwide are impatiently waiting for publication of the results. 
There are still large variations between European countries in strategies of can-
cer care and subsequently, in cancer outcome. EURECCA (European Registration 
of cancer care) is a population-based colorectal cancer registry, but also involves 
multidisciplinary panel of experts, founded by leading professionals in all fields of 
medicine involved in cancer care. It’s primary objective is to reduce treatment vari-
ances between countries or even within the same country and improve colorectal 
cancer care in Europe through registry, feedback and definition of core strategies 
in diagnostics, staging and treatment of colorectal cancer patients [18]. The panel 
formed a number of expert consensuses (with large to minimal equivocality); con-
sensus is achieved for every step in diagnostic and treatment process of colorectal 
cancer patients, but panel strongly supports multidisciplinary team discussions in 
decision making for each patient. Also, diagnostic and treatment algorithms were 
developed and published by the panel, in order to provide up-to-date support to 
multidisciplinary teams involved in care for colorectal patients [18]. 
In conclusion, decision for the treatment of rectal cancer must mandatory be 
multidisciplinary. Surgical resection remains the therapeutic cornerstone, but the 
addition of neoadjuvant radiotherapy and chemotherapy is showing substantial be-
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nefits. It is therefore necessary to subject all rectal cancer patients to multidiscipli-
nary facility, where patients can be treated according to all actual recommendations 
and by that they receive best possible care and chance to fight the disease. Naturally, 
for every individual rectal cancer patient, individualized treatment plans based on 
a well-defined protocols should be designed. 
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Sažetak
Važnost multidisciplinarnog pristupa u liječenju karcinoma rektuma
Kolorektalni karcinom je treća maligna bolest po učestalosti u svijetu, te predstavlja znača-
jan javnozdravstveni problem. Multidisciplinarni pristup danas je uobičajen kod dijagnostike i 
liječenja onkoloških bolesti, a karcinom rektuma tipičan je primjer za važnost suradnje različitih 
medicinskih disciplina u postizanju optimalnog terapijskog učinka. U ovom preglednom radu pri-
kazan je kratak presjek najvažnijih studija koje su definirale optimalni pristup liječenju bolesnika 
sa lokalno uznapredovalim karcinomom rektuma. Današnje smjernice i preporuke za liječenje 
karcinoma rektuma stadija II i III uključuju preoperativnu radioterapiju sa ili bez konkomitantne 
kemoterapije, te radikalan kirurški zahvat (uz obaveznu totalnu mezorektalnu eksciziju-TME). 
Takvim se multidisciplinarnim pristupom kod tih bolesnika značajno reducirala stopa lokalnih 
recidiva, te povećala stopa patoloških kompletnih odgovora i zahvata sa očuvanjem analnog 
sfinktera, uz nisku stopu terapijske toksičnosti. Daljnje studije koje ispituju nove sistemske tera-
pije (imunoterapija-konjugati antitijela i lijekova), kao i modernije radioterapijske tehnike (IMRT, 
IGRT, VMAT ) kod bolesnika sa karcinomom rektuma, a kojima bi se dodatno unaprijedili tera-
pijski ishodi, su u tijeku.
Ključne riječi: karcinom rektuma; preoperativna (neoadjuvantna) kemoradioterapija; kom-
pletna mezorektalna ekscizija; multidisciplinarno liječenje.
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